Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019 Journal Article
| Authors: | Bhimani, J.; O’Connell, K.; Ergas, I. J.; Foley, M.; Gallagher, G. B.; Griggs, J. J.; Heon, N.; Kolevska, T.; Kotsurovskyy, Y.; Kroenke, C. H.; Laurent, C. A.; Liu, R.; Nakata, K. G.; Persaud, S.; Rivera, D. R.; Roh, J. M.; Tabatabai, S.; Valice, E.; Bowles, E. J. A.; Bandera, E. V.; Kushi, L. H.; Kantor, E. D. |
| Article Title: | Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019 |
| Abstract: | Background: Little is known about how use of chemotherapy has evolved in breast cancer patients. We therefore describe chemotherapy patterns for women with stage I-IIIA breast cancer in the Optimal Breast Cancer Chemotherapy Dosing (OBCD) Study using data from KPNC (Kaiser Permanente Northern California) and KPWA (Kaiser Permanente Washington). Findings: Among 33,670 women, aged 18 + y, diagnosed with primary stage I-IIIA breast cancer at KPNC and KPWA from 2006 to 2019, we explored patterns of intravenous chemotherapy use, defined here as receipt of intravenous cytotoxic drugs and/or anti-HER2 therapies. We evaluated trends in chemotherapy receipt, duration over which chemotherapy was received, and number of associated infusion visits. In secondary analyses, we stratified by receipt of anti-HER2 therapies (trastuzumab and/or pertuzumab), given their longer duration. 38.9% received chemotherapy intravenously, declining from 40.2% in 2006 to 35.6% in 2019 (p-trend < 0.001). Among 13,089 women receiving chemotherapy, neoadjuvant treatment increased (4.1–14.7%; p-trend < 0.001), as did receipt of anti-HER2 therapies (20.8–30.9%) (p-trend < 0.001). The average treatment duration increased (5.3 to 6.0 months; p-trend < 0.001), as did the number of infusion visits (10.8 to 12.5; p-trend < 0.001). For those receiving anti-HER2 therapies, treatment duration and average number of visits decreased; among those not receiving anti-HER2 therapies, number of visits increased, with no change in duration. Conclusions: While the prevalence of chemotherapy receipt has decreased over time, the use of neoadjuvant chemotherapy has increased, as has use of anti-HER2 therapies; duration and number of administration visits have also increased. Understanding these trends is useful to inform clinical and administrative planning. © The Author(s) 2024. |
| Keywords: | adult; cancer chemotherapy; controlled study; aged; middle aged; young adult; major clinical study; cytotoxic agent; treatment duration; treatment planning; chemotherapy, adjuvant; neoadjuvant therapy; chemotherapy; cancer staging; antineoplastic agent; neoplasm staging; metabolism; breast cancer; antineoplastic combined chemotherapy protocols; prevalence; epidermal growth factor receptor 2; cohort analysis; pathology; breast neoplasms; health insurance; early cancer; adjuvant chemotherapy; breast tumor; drug infusion; receptor, erbb-2; neoadjuvant chemotherapy; epidemiology; drug therapy; trastuzumab; trend study; drug use; pertuzumab; secondary analysis; erbb2 protein, human; antineoplastics; very elderly; humans; human; female; article |
| Journal Title: | Breast Cancer Research |
| Volume: | 26 |
| ISSN: | 1465-5411 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2024-06-13 |
| Start Page: | 101 |
| Language: | English |
| DOI: | 10.1186/s13058-024-01822-9 |
| PUBMED: | 38872192 |
| PROVIDER: | scopus |
| PMCID: | PMC11170793 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Corresponding authors is MSK author: Elizabeth D. Kanto -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work